Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 8;7(3):618-623.
doi: 10.1016/j.ekir.2021.11.033. eCollection 2022 Mar.

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

Shruti Gupta  1 , Tiffany Caza  2 , Sandra M Herrmann  3 , Vipulbhai C Sakhiya  4 , Kenar D Jhaveri  4
Affiliations

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

Shruti Gupta et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histopathology of cyclin-dependent kinase inhibitor-associated acute kidney injury. (a) Interstitial fibrosis and disproportionate tubular atrophy throughout the cortex, Jones methenamine silver, 100×, scale bar = 10 μm. (b) Normal glomeruli without matrix expansion or proliferative changes, periodic acid–Schiff, 200×, scale bar = 50 μm. (c) Interstitial edema and mixed interstitial inflammation, hematoxylin + eosin, 200×, scale bar = 50 μm. (d) Neutrophil-rich inflammation and tubulorrhexis, hematoxylin + eosin, 400×, scale bar = 20 μm. (e) Mild lymphocytic interstitial inflammation and acute tubular injury (apical cytoplasmic blebbing, epithelial cell simplification, and ectasia of tubular profiles), hematoxylin + eosin, 400×, scale bar = 20 μm. (f) Interstitial edema separating tubular profiles and acute tubular injury with epithelial cell simplification, reactive and regenerative nuclear changes, and dilation, hematoxylin + eosin, 400×, scale bar = 20 μm.
See this image and copyright information in PMC

References

    1. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. doi: 10.1146/annurev-med-070909-182917. - DOI - PMC - PubMed
    1. Finn R.S., Aleshin A., Slamon D.J. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18:17. doi: 10.1186/s13058-015-0661-5. - DOI - PMC - PubMed
    1. Finn R.S., Martin M., Rugo H.S., et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936. doi: 10.1056/NEJMoa1607303. - DOI - PubMed
    1. Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [published correction appears in N Engl J Med. 2018;379:2582] N Engl J Med. 2016;375:1738–1748. doi: 10.1056/NEJMoa1609709. - DOI - PubMed
    1. Cristofanilli M., Turner N.C., Bondarenko I., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [published correction appears in Lancet Oncol. 2016;17:e136 and Lancet Oncol. 2016;17:e270] Lancet Oncol. 2016;17:425–439. doi: 10.1016/S1470-2045(15)00613-0. - DOI - PubMed

LinkOut - more resources